A validated method for the determination of paracetamol and its glucuronide and sulphate metabolites in the urine of HIV+/AIDS patients using wavelength-switching UV detection

Journal of Pharmaceutical and Biomedical Analysis

Volumn 17, Issue 6-7, 1998, Pages 1191-1197

  Di Girolamo, A ^a,b   O'Neill, W M ^c   Wainer, I W ^d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ABBOTT LABORATORIES   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glucuronidation; HIV+ AIDS; Paracetamol; Phase II metabolism; Phenotyping; Sulfation

Indexed keywords

DRUG METABOLITE; PARACETAMOL; PARACETAMOL SULFATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SULFATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; URINE;

ACETAMINOPHEN; ACETONITRILES; ACQUIRED IMMUNODEFICIENCY SYNDROME; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONATES; HIV SEROPOSITIVITY; HUMANS; HYDROGEN-ION CONCENTRATION; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SODIUM ACETATE; SULFATES; TRIFLUOROACETIC ACID; ULTRAVIOLET RAYS;

EID: 0032437031     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(98)00084-3     Document Type: Article

References (21)

1. [1] J. Ducharme, S. Abdullah, I.W. Wainer, J. Chromatogr B 678 (1996) 113-128.
2. [2] F.J. Gonzalez, J.R. Idle, Clin. Pharmacokinet. 26 (1994) 59-70.
3. [3] B.G. Katzung (Ed.), In Basic and Clinical Pharmacology, Appleton and Lange, Norwalk, 6th edn., 1995, pp. 48-59.
4. [4] D.V. Parke, C. Ioannides, Annu. Rev. Nutr. 1 (1981) 207-234.
5. [5] B.L. Lee, D. Wong, N.L. Benowitz, P.M. Sullam, Clin. Pharmacol. Ther. 53 (1993) 529-535.
6. [6] C. Délomenie, D.M. Grant, P. Mathetier-Fuscade, et al., Br. J. Clin. Pharmacol. 38 (1994) 581-582.
7. [7] W.M. O'Neill, B.M. Gilfix, A. Di Girolamo, C.M. Tsoukas, I.W. Wainer, Clin. Pharmacol. Ther. 62 (1997) 261-271.
8. [8] A. Di Girolamo, W.M. O'Neill, B.M. Gilfix, D.A. Flockhart, C.M. Tsoukas, I.W. Wainer, J. Acquir. Immune Defic Syndr. (1997) submitted.
9. [9] G.S.N. Lau, J.A.J.H. Critchley, J. Pharm. Biomed. Anal. 12 (1994) 1563-1572.
10. [10] S.S. Al-Obaidy, A. Li Wan Po, P.J. McKiernan, et al., J. Pharm. Biomed. Anal. 13 (1995) 1033-1039.
11. [11] L.F. Prescott, Br. J. Clin. Pharmacol. 10 (1980) 291S-298S.
12. [12] R.E. Galinsky, G.B. Corcoran, Drug Metab. Dispos. 3 (1987) 348-354.
13. [13] C.H. Jackson, N.C. MacDonald, J.W.D. Cornett, Can. Med. Assoc. J. 131 (1984) 25-37.
14. [14] G.G. Gibson, P. Skett (Eds.), In Introduction to Drug Metabolism, 2nd edn., Chapman and Hall, London, 1994, pp. 171-172.
15. [15] J.A.J.H. Critchley, G.R. Nimmo, C.A. Gregson, et al., Br. J. Clin. Pharmacol. 22 (1986) 649-657.
16. [16] H.G. Knox, J. Jurand, J. Chromatogr. 142 (1977) 651-670.
17. [17] D. Blair, B.H. Rumack, Clin. Chem. 23 (1977) 743-745.
18. [18] G.R. Gottelli, P.M. Kabra, L.J. Morton, Clin. Chem. 23 (1977) 957-959.
19. [19] R.A. Horvitz, P.I. Jatlow, Clin. Chem 23 (1977) 1596-1598.
20. [20] C.G. Fletterick, T.H. Grove, D.C. Hohnadel, Clin. Chem. 25 (1979) 409-412.
21. [21] C.A. Korduba, R.F. Petruzzi, J. Pharm. Sci. 73 (1984) 117-119.